CDT EQUITY INC. Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount
CDT EQUITY INC. (CDT) had Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount of $1.30 million as of 2026-06-30, per its S-1 filed 2026-09-08.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions · last filed 2026-09-08
- 2026-06-30: Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount $1.30M.
- 2026-03-31: Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount $1.40M.
- 2025-12-31: Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount $2.80M.
- 2025-09-30: Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount $1.40M.
| Period end | Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount |
|---|---|
| 2026-06-30 | $1.30M S-1 · filed 2026-09-08 |
| 2026-03-31 | $1.40M 10-Q · filed 2026-07-15 |
| 2025-12-31 | $2.80M S-1 · filed 2026-09-08 |
| 2025-09-30 | $1.40M 10-Q · filed 2025-11-13 |
| 2025-06-30 | $1.60M 10-Q · filed 2025-08-14 |
| 2025-03-31 | $2.00M 10-Q/A · filed 2025-08-14 |
| 2024-12-31 | $2.40M 10-K · filed 2025-03-28 |
| 2024-09-30 | $2.70M 10-Q · filed 2024-11-14 |
| 2024-06-30 | $3.10M 10-Q/A · filed 2024-11-14 |
| 2024-03-31 | $3.70M 10-Q/A · filed 2024-11-14 |
| 2023-12-31 | $4.10M 10-K · filed 2024-04-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aditxt, Inc. (ADTX) | United States | $0.000B | |
| Rafael Holdings, Inc. (RFL) | United States | $0.000B | -0.00 |
| Protagenic Therapeutics, Inc.\new (PTIX) | United States | $0.001B | |
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B |